The Journal of Clinical Endocrinology & Metabolism, 110 (1), 115
A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells
Neither has been directly compared to the other, and cross-trial comparisons are limited by differences in patient populations, dose escalation, and trial duration
Balancing GLP-1 Clinical Benefits with Financial Sustainability Pain Point : Plan sponsors are challenged to provide access to promising new medications while also controlling costs for both the plan and employees
This nickname comes from the fact that the drug acts on three receptors: GLP-1, GIP, and glucagon
Effects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity